The cIMPACT-NOW 8 (2024) update refines meningioma classification by incorporating copy number variations (CNV) and reconsidering brain invasion, whose presence alone is no longer sufficient for Grade 2 classification. 1p loss with 22q deletion warrants Grade 2, while additional genetic alterations improve risk stratification. Some biomarkers remain under investigation, and molecular classification may guide patient selection for radiotherapy and targeted therapies.
Keywords
Central nervous system, meningioma, copy number variation (CNV), methylation